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Background: Patients undergoing percutaneous coronary interventions (PCI) have been shown to be at risk for recurrent events if they are low 
responders to clopidogrel. However, whether the increased platelet reactivity accompanying an acute coronary syndrome (ACS) is a cause for low 
response to clopidogrel is unknown. Accordingly, we investigated the impact of clinical presentation (ACS vs. Stable Angina, SA) on platelet reactivity 
and clopidogrel response in patients undergoing PCI. 
Methods: Consecutive patients undergoing PCI at the University of Pittsburgh were enrolled. Testing was performed >12 hrs following the PCI using 
light transmission aggregometry (LTA, using ADP and collagen as agonists) and the point of care VerifyNow P2Y12 assay (VN). 
Results: A total of 176 patients were studied, including 83 patients with SA and 93 with ACS). There were more females and more smokers in the 
ACS group. The medications, including proton pump inhibitors and statins, were similar between the 2 groups. There were no differences in collagen-
induced platelet aggregation between the ACS (75.3±17.6%) and SA (76.5±14.6%) groups, respectively (p=0.69). The residual platelet reactivity to 
20 μM ADP by LTA was also similar between the groups (% residual aggregation 44.9±22.2 ACS vs. 41.6± 18.0 SA, p=0.29), a finding confirmed by 
the VN P2Y12 assay (P2Y12 reaction units, PRUs 208.9±93.6 ACS vs. 205.4±85.6 SA, p=0.8). Thus, these findings demonstrate lack of increased 
platelet reactivity the day after PCI in the ACS group. When clopidogrel response was expressed as a categorical variable (decreased response 
>240 PRU using VN), the number of low-responders was similar in the 2 groups (41% in the ACS group vs. 35% in the SA group, P=NS). However, the 
subgroup of ACS patients who were already on clopidogrel at the time of presentation had more low-responders compared with the thyenopiridine 
naïve patients (58% vs. 32%, p<0.05), which was not true for the SA group. 
Conclusion: Our analysis demonstrates that initial clinical presentation does not directly affect platelet reactivity the day after PCI. An increased 
prevalence of low-responders was found in the patients who had ACS while on clopidogrel.
